Tags

Type your tag names separated by a space and hit enter

Photoactivated Chromophore for Moderate to Severe Infectious Keratitis as an Adjunct Therapy: A Randomized Controlled Trial.
Am J Ophthalmol. 2016 May; 165:94-9.AJ

Abstract

PURPOSE

To evaluate the efficacy of photoactivated chromophore for infectious keratitis (PACK-CXL) in the treatment of patients with moderate to severe infectious keratitis as adjunct therapy to the topical medication treatment.

DESIGN

Randomized clinical trial.

METHODS

Thirty eyes from 30 patients with moderate to severe infectious keratitis were randomized to receive either standard treatment plus PACK-CXL (n = 15) or standard treatment alone (control group, n = 15). The primary outcome was the sizes of stromal infiltrates measured on slit-lamp photographs 30 days after treatment. The secondary outcomes were the sizes of epithelial defects, the complication rates, and best pinhole-corrected visual acuity (BPVA).

RESULTS

The median (interquartile range [IQR]) sizes of stromal infiltrates at day 30 were 5.0 mm(2) (0-23.0 mm(2)) in the PACK-CXL group and 10.6 mm(2) (1.1-16.3 mm(2)) in the control group (median difference 0, 95% CI -7.0 to 0, P = .66). The median (IQR) sizes of epithelial defects were 0.7 mm(2) (0-6.3 mm(2)) and 4.6 mm(2) (0-10.2 mm(2)) in the PACK-CXL group and control group, respectively (median difference -3.0, 95% CI -0.8 to 0, P = .41). The complication rates and BPVA after treatment were comparable between groups.

CONCLUSIONS

Standard treatment combined with PACK-CXL did not provide any advantageous effect over standard treatment alone in moderate to severe infectious keratitis over a 30-day period.

Authors+Show Affiliations

Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Electronic address: vannaruts@gmail.com.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26949133

Citation

Kasetsuwan, Ngamjit, et al. "Photoactivated Chromophore for Moderate to Severe Infectious Keratitis as an Adjunct Therapy: a Randomized Controlled Trial." American Journal of Ophthalmology, vol. 165, 2016, pp. 94-9.
Kasetsuwan N, Reinprayoon U, Satitpitakul V. Photoactivated Chromophore for Moderate to Severe Infectious Keratitis as an Adjunct Therapy: A Randomized Controlled Trial. Am J Ophthalmol. 2016;165:94-9.
Kasetsuwan, N., Reinprayoon, U., & Satitpitakul, V. (2016). Photoactivated Chromophore for Moderate to Severe Infectious Keratitis as an Adjunct Therapy: A Randomized Controlled Trial. American Journal of Ophthalmology, 165, 94-9. https://doi.org/10.1016/j.ajo.2016.02.030
Kasetsuwan N, Reinprayoon U, Satitpitakul V. Photoactivated Chromophore for Moderate to Severe Infectious Keratitis as an Adjunct Therapy: a Randomized Controlled Trial. Am J Ophthalmol. 2016;165:94-9. PubMed PMID: 26949133.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Photoactivated Chromophore for Moderate to Severe Infectious Keratitis as an Adjunct Therapy: A Randomized Controlled Trial. AU - Kasetsuwan,Ngamjit, AU - Reinprayoon,Usanee, AU - Satitpitakul,Vannarut, Y1 - 2016/03/03/ PY - 2015/10/29/received PY - 2016/02/23/revised PY - 2016/02/24/accepted PY - 2016/3/8/entrez PY - 2016/3/8/pubmed PY - 2017/4/28/medline SP - 94 EP - 9 JF - American journal of ophthalmology JO - Am J Ophthalmol VL - 165 N2 - PURPOSE: To evaluate the efficacy of photoactivated chromophore for infectious keratitis (PACK-CXL) in the treatment of patients with moderate to severe infectious keratitis as adjunct therapy to the topical medication treatment. DESIGN: Randomized clinical trial. METHODS: Thirty eyes from 30 patients with moderate to severe infectious keratitis were randomized to receive either standard treatment plus PACK-CXL (n = 15) or standard treatment alone (control group, n = 15). The primary outcome was the sizes of stromal infiltrates measured on slit-lamp photographs 30 days after treatment. The secondary outcomes were the sizes of epithelial defects, the complication rates, and best pinhole-corrected visual acuity (BPVA). RESULTS: The median (interquartile range [IQR]) sizes of stromal infiltrates at day 30 were 5.0 mm(2) (0-23.0 mm(2)) in the PACK-CXL group and 10.6 mm(2) (1.1-16.3 mm(2)) in the control group (median difference 0, 95% CI -7.0 to 0, P = .66). The median (IQR) sizes of epithelial defects were 0.7 mm(2) (0-6.3 mm(2)) and 4.6 mm(2) (0-10.2 mm(2)) in the PACK-CXL group and control group, respectively (median difference -3.0, 95% CI -0.8 to 0, P = .41). The complication rates and BPVA after treatment were comparable between groups. CONCLUSIONS: Standard treatment combined with PACK-CXL did not provide any advantageous effect over standard treatment alone in moderate to severe infectious keratitis over a 30-day period. SN - 1879-1891 UR - https://www.unboundmedicine.com/medline/citation/26949133/Photoactivated_Chromophore_for_Moderate_to_Severe_Infectious_Keratitis_as_an_Adjunct_Therapy:_A_Randomized_Controlled_Trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9394(16)30080-0 DB - PRIME DP - Unbound Medicine ER -